Table 1.

Association between CYP1B1 variants and prostate cancer in the entire family-based study sample, stratified by disease aggressiveness

CYP1B1 variantsEntire sampleLow aggressive*High aggressive
Cases/controlsOR (95% CI)PCases/controlsOR (95% CI)PCases/controlsOR (95% CI)P
Genotypes
G355T
    GG216 of 2471.0090 of 931.00109 of 1361.00
    GT178 of 1971.06 (0.75-1.50)0.7482 of 1000.73 (0.45-1.19)0.2089 of 861.90 (1.09-3.31)0.02
    TT43 of 351.68 (0.87-3.25)0.1214 of 141.00 (0.34-2.91)0.9927 of 183.73 (1.39-10.0)0.009
C4326G
    CC145 of 1511.0069 of 651.0071 of 761.00
    GC185 of 2050.86 (0.56-1.30)0.4768 of 900.54 (0.28-1.05)0.07105 of 1061.03 (0.57-1.89)0.91
    GG109 of 1230.75 (0.43-1.28)0.2951 of 520.67 (0.30-1.49)0.3249 of 580.79 (0.35-1.77)0.57
Diplotypes
G355T-C4326G
    G-G/G-G89 of 1011.0041 of 411.0040 of 481.00
    G-C/G-G90 of 1061.08 (0.61-1.89)0.8032 of 381.38 (0.54-3.54)0.5152 of 650.71 (0.33-1.51)0.37
    G-C/G-C37 of 401.26 (0.59-2.65)0.5517 of 142.64 (0.78-8.89)0.1217 of 230.65 (0.23-1.82)0.42
    G-C/T-C71 of 851.08 (0.59-1.97)0.8038 of 401.44 (0.59-352)0.4232 of 400.95 (0.38-2.39)0.91
    T-C/G-G90 of 941.24 (0.75-2.05)0.4135 of 510.72 (0.33-1.54)0.3949 of 372.22 (1.07-4.61)0.03
    T-C/T-C37 of 262.17 (1.01-4.67)0.0514 of 112.24 (0.73-6.81)0.1622 of 133.27 (1.02-10.5)0.05
    Composites§23 of 270.68 (0.27-1.73)0.429 of 120.44 (0.09-2.09)0.3013 of 141.20 (0.30-4.89)0.79
T-C
    None235 of 2691.0099 of 1041.00118 of 1461.00
    One copy165 of 1841.11 (0.77-1.58)0.5873 of 920.74 (0.44-1.23)0.2485 of 811.99 (1.15-3.47)0.01
    Two copies37 of 262.07 (1.03-4.16)0.0414 of 111.55 (0.53-4.58)0.4222 of 134.00 (1.36-11.8)0.01
  • * Includes cases with Gleason score <7 and tumor stage <T2C and their brothers.

  • Includes cases with Gleason score ≥ 7 and/or tumor stage ≥T2C and their brothers.

  • Adjusted for age.

  • § Includes diplotypes T-G/T-G, T-G/G-G, and T-C/T-G.

  • Presence of haplotype T-C.